Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan